 2008 |
| |
| METABOLEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL OF MBX-8025 |
|
| November 18, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025. |
| |
|
More > |
| |
| METABOLEX ANNOUNCES POSITIVE RESULTS FROM PHASE 1a CLINICAL TRIAL OF MBX-2982 |
|
| November 12, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982. |
| |
|
More > |
| |
| TWO METABOLEX PROJECTS RECOGNIZED IN WINDHOVER’S TOP 10 LISTS FOR PARTNERING OPPORTUNITIES
|
|
| November 3, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover’s “Top 10 most interesting projects available for partnering” in their respective categories. |
| |
|
More > |
| |
| METABOLEX ANNOUNCES ELECTION OF ROBERT L. ZERBE TO BOARD OF DIRECTORS |
|
| September 30, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new therapeutics for the treatment of diabetes and related metabolic disorders, announced that Robert L. Zerbe, M.D., has been elected to its Board of Directors. |
| |
|
More > |
| |
| METABOLEX NAMES ZHAO, MARTIN TO EXECUTIVE POSTS |
|
| July 7, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that it has promoted Zuchun ‘Spring’ Zhao to Vice President of Chemical Sciences, and Robert Martin to Vice President of Project and Portfolio Management. |
| |
|
More > |
| |
| METABOLEX COMPLETES PATIENT ENROLLMENT IN PHASE 2 TRIAL OF MBX-8025 FOR TREATMENT OF DYSLIPIDEMIA |
|
| June 16, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has completed enrollment in a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides. |
| |
|
More > |
| |
| METABOLEX APPOINTS DONALD HILL AS CHIEF FINANCIAL OFFICER |
|
| April 14, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions... |
| |
|
More > |
| |
| METABOLEX INITIATES PHASE 1 TRIAL OF MBX-2982 |
|
| March 26, 2008 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has dosed the first cohort of healthy subjects in a Phase 1 clinical trial of MBX-2982, a potential first-in-class treatment for type 2 diabetes ... |
| |
|
More > |
| |
